Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of these agents is to ...

    Research Article last updated 03/03/2015 - 2:41pm.

  2. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

    ... the impact of TP53 mutations in MDS treated with azacitidine (AZA) remains unclear. We analyzed TP53 mutations in 62 ...

    Research Article last updated 06/02/2014 - 11:17am.

  3. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

    ... reported to identify differential survival among azacitidine -treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a ...

    Research Article last updated 04/23/2014 - 12:10pm.

  4. AAMDSIF Summer Fellowship Grant Program

    ... investigated DNA response to two drugs, vosaroxin and azacitidine , by comparing samples of patient DNA before and after ... in tumor cells caused by vosaroxin and an additional drug, azacitidine, which is currently the frontline therapy for MDS. We will ...

    Page last updated 05/17/2017 - 1:29pm.

  5. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

    ... and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of ... of MDS. Combination treatment strategies using an azacitidine backbone are demonstrating promising early results. Expanding the ...

    Research Article last updated 01/08/2014 - 9:15am.

  6. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic ... trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as ...

    Research Article last updated 06/15/2012 - 2:13pm.

  7. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 10/02/2014 - 10:30am.

  8. Update on the pharmacotherapy for myelodysplastic syndromes

    ... of these complex malignancies: lenalidomide , azacitidine and decitabine . AREAS COVERED: This review ...

    Research Article last updated 08/21/2014 - 9:23am.

  9. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes

    ... appropriate for all patients. Two demethylating agents, azacitidine and decitabine , are approved for treatment of MDS, ...

    Research Article last updated 08/04/2014 - 8:31am.

  10. Current therapy of myelodysplastic syndromes.

    ... (MDS). On the therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last ...

    Research Article last updated 09/03/2013 - 12:03pm.